EUVIMEDEUVIMED entdecken
Crossref

Progression-Free Survival Should Not Be Used as a Primary End Point for Registration of Anticancer Drugs

Christopher M Booth iD, Elizabeth A Eisenhauer iD, Bishal Gyawali iD, Ian F Tannock iD

Journal of Clinical Oncology · 10.11.2023 · 41 (32) · 4968-4972

DOI: 10.1200/jco.23.01423 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.11.2023. Verfasst von Christopher M Booth und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Care and Epidemiology, Queen's University Cancer Research Institute, Kingston, Canada. Hauptthemen laut MEDLINE: Antineoplastic Agents. Die Arbeit wurde bisher 70-mal zitiert (Crossref) und nennt 58 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsHumansProgression-Free SurvivalDisease-Free Survival

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Division of Cancer Care and Epidemiology, Queen's University Cancer Research Institute, Kingston, Canada.
  • Department of Oncology, Queen's University, Kingston, Canada.
  • Department of Public Health Sciences, Queen's University, Kingston, Canada.
  • Division of Medical Oncology, Princess Margaret Cancer Centre and University of Toronto, Toronto, Canada.

ORCID-Profile: Christopher M Booth, Elizabeth A Eisenhauer, Bishal Gyawali, Ian F Tannock

Zitieren

APA

Booth, C. M., Eisenhauer, E. A., Gyawali, B., & Tannock, I. F. (2023). Progression-Free Survival Should Not Be Used as a Primary End Point for Registration of Anticancer Drugs. Journal of Clinical Oncology, 41(32), 4968-4972. https://doi.org/10.1200/jco.23.01423

Vancouver

Booth CM, Eisenhauer EA, Gyawali B, Tannock IF. Progression-Free Survival Should Not Be Used as a Primary End Point for Registration of Anticancer Drugs. Journal of Clinical Oncology. 2023;41(32):4968-4972. doi:10.1200/jco.23.01423

BibTeX
@article{Booth2023,
  author = {Booth, Christopher M and Eisenhauer, Elizabeth A and Gyawali, Bishal and Tannock, Ian F},
  title = {Progression-Free Survival Should Not Be Used as a Primary End Point for Registration of Anticancer Drugs},
  journal = {Journal of Clinical Oncology},
  year = {2023},
  volume = {41},
  number = {32},
  pages = {4968--4972},
  doi = {10.1200/jco.23.01423}
}
Kostenlos starten →